Plasmin in urine from patients with type 2 diabetes and treatment-resistant hypertension activates ENaC in vitro

Journal of Hypertension

Volumn 32, Issue 8, 2014, Pages 1672-1677

  Buhl, Kristian B ^a   Oxlund, Christina S ^b   Friis, Ulla G ^a   Svenningsen, Per ^a   Bistrup, Claus ^c   Jacobsen, Ib A ^b   Jensen, Boye L ^a  

^a UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

^b Department of Endocrinology Research Unit for Cardiovascular and Metabolic Prevention   (Denmark)

^c ODENSE UNIVERSITY HOSPITAL   (Denmark)

Author keywords

aldosterone; diuretics; kidney

Indexed keywords

ALBUMIN; ANGIOTENSIN; CREATININE; EPITHELIAL SODIUM CHANNEL; GLYCOSYLATED HEMOGLOBIN; PLASMIN; PLASMINOGEN; PROTEINASE;

ADULT; AGED; ARTICLE; BLOOD PRESSURE MONITORING; CREATININE URINE LEVEL; DIASTOLIC BLOOD PRESSURE; FEMALE; HUMAN; IN VITRO STUDY; MAJOR CLINICAL STUDY; MALE; MICROALBUMINURIA; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RESISTANT HYPERTENSION; SYSTOLIC BLOOD PRESSURE; ALBUMINURIA; BLOOD PRESSURE; DRUG RESISTANCE; HYPERTENSION; PATHOPHYSIOLOGY; PHYSIOLOGY; URINE;

ALBUMINURIA; BLOOD PRESSURE; CREATININE; DIABETES MELLITUS, TYPE 2; DRUG RESISTANCE; EPITHELIAL SODIUM CHANNELS; FIBRINOLYSIN; HUMANS; HYPERTENSION; PLASMINOGEN;

EID: 84904035904     PISSN: 02636352     EISSN: 14735598     Source Type: Journal    
DOI: 10.1097/HJH.0000000000000216     Document Type: Article

References (34)

1. Svenningsen P, Bistrup C, Friis UG, Bertog M, Haerteis S, Krueger B, et al. Plasmin in nephrotic urine activates the epithelial sodium channel. J Am Soc Nephrol 2009; 20:299-310.
2. Andersen RF, Buhl KB, Jensen BL, Svenningsen P, Friis UG, Jespersen B, et al. Remission of nephrotic syndrome diminishes urinary plasmin content and abolishes activation of ENaC. Pediatr Nephrol 2013; 28:1227-1234.
3. Buhl KB, Friis UG, Svenningsen P, Gulaveerasingam A, Ovesen P, Frederiksen-Moller B, et al. Urinary plasmin activates collecting duct ENaC current in preeclampsia. Hypertension 2012; 60:1346-1351.
4. Svenningsen P, Uhrenholt TR, Palarasah Y, Skjodt K, Jensen BL, Skott O. Prostasin-dependent activation of epithelial Na channels by low plasmin concentrations. Am J Physiol Regul Integr Comp Physiol 2009; 297:R1733-R1741.
5. Passero CJ, Mueller GM, Rondon-Berrios H, Tofovic SP, Hughey RP, Kleyman TR. Plasmin activates epithelial Na channels by cleaving the gamma subunit. J Biol Chem 2008; 283:36586-36591.
6. Deschenes G, Wittner M, Stefano A, Jounier S, Doucet A. Collecting duct is a site of sodium retention in PAN nephrosis: A rationale for amiloride therapy. J Am Soc Nephrol 2001; 12:598-601. (Pubitemid 32180030)
7. Ichikawa I, Rennke HG, Hoyer JR, Badr KF, Schor N, Troy JL, et al. Role for intrarenal mechanisms in the impaired salt excretion of experimental nephrotic syndrome. J Clin Invest 1983; 71:91-103. (Pubitemid 13170241)
8. Deschenes G, Guigonis V, Doucet A. Molecular mechanism of edema formation in nephrotic syndrome. Arch Pediatr 2004; 11:1084-1094. (Pubitemid 39233349)
9. Shimkets RA, Warnock DG, Bositis CM, Nelson-Williams C, Hansson JH, Schambelan M, et al. Liddle's syndrome: heritable human hypertension caused by mutations in the beta subunit of the epithelial sodium channel. Cell 1994; 79:407-414. (Pubitemid 24346056)
10. Hajjar I, Kotchen TA. Trends in prevalence, awareness, treatment, and control of hypertension in the United States, 1988-2000. JAMA 2003; 290:199-206. (Pubitemid 37430058)
11. Sarafidis PA. Epidemiology of resistant hypertension. J Clin Hypertens (Greenwich) 2011; 13:523-528.
12. Calhoun DA, Jones D, Textor S, Goff DC, Murphy TP, Toto RD, et al. Resistant hypertension: diagnosis, evaluation, and treatment. A scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Hypertension 2008; 51:1403-1419.
13. de SouzaF F. Muxfeldt ES, Salles GF. Prognostic factors in resistant hypertension: implications for cardiovascular risk stratification and therapeutic management. Expert Rev Cardiovasc Ther 2012; 10:735-745.
14. Weir MR. Albuminuria predicting outcome in diabetes: incidence of microalbuminuria in Asia-Pacific Rim. Kidney Int Suppl 2004; 92: S38-S39. (Pubitemid 43361427)
15. Ito H, Mifune M, Abe M, Oshikiri K, Antoku S, Takeuchi Y, et al. Hypertension resistant to antihypertensive agents commonly occurs with the progression of diabetic nephropathy in Japanese patients with type 2 diabetes mellitus: A prospective observational study. BMC Nephrol 2012; 13:48.
16. Bigazzi R, Bianchi S, Baldari D, Sgherri G, Baldari G, Campese VM. Microalbuminuria in salt-sensitive patients. A marker for renal and cardiovascular risk factors. Hypertension 1994; 23:195-199. (Pubitemid 24050280)
17. Nesovic M, Stojanovic M, Nesovic MM, Ciric J, Zarkovic M. Microalbuminuria is associated with salt sensitivity in hypertensive patients. J Hum Hypertens 1996; 10:573-576. (Pubitemid 26402312)
18. Strojek K, Grzeszczak W, Lacka B, Gorska J, Keller CK, Ritz E. Increased prevalence of salt sensitivity of blood pressure in IDDM with and without microalbuminuria. Diabetologia 1995; 38:1443-1448.
19. Cubeddu LX, Hoffmann IS, Aponte LM, Nunez-Bogesits R, Medina-Suniaga H, Roa M, et al. Role of salt sensitivity, blood pressure, and hyperinsulinemia in determining high upper normal levels of urinary albumin excretion in a healthy adult population. Am J Hypertens 2003; 16:343-349. (Pubitemid 36570969)
20. Cifkova R, Erdine S, Fagard R, Farsang C, Heagerty AM, Kiowski W, et al. Practice guidelines for primary care physicians: 2003 ESH/ESC hypertension guidelines. J Hypertens 2003; 21:1779-1786. (Pubitemid 37290093)
21. Oxlund CS, Henriksen JE, Tarnow L, Schousboe K, Gram J, Jacobsen IA. Lowdose spironolactone reduces blood pressure in patients with resistant hypertension and type 2 diabetes mellitus: A double blind randomized clinical trial. J Hypertens 2013; 31:2094-2102.
22. Yip GW, So HK, Li AM, Tomlinson B, Wong SN, Sung RY. Validation of A&D TM-2430 upper-arm blood pressure monitor for ambulatory blood pressure monitoring in children and adolescents, according to the British Hypertension Society protocol. Blood Press Monit 2012; 17:76-79.
23. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: A new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 1999; 130:461-470. (Pubitemid 29135798)
24. Afkhami-Ardekani M, Modarresi M, Amirchaghmaghi E. Prevalence of microalbuminuria and its risk factors in type 2 diabetic patients. Indian J Nephrol 2008; 18:112-117.
25. Eide IK, Torjesen PA, Drolsum A, Babovic A, Lilledahl NP. Low-renin status in therapy-resistant hypertension: A clue to efficient treatment. J Hypertens 2004; 22:2217-2226. (Pubitemid 39463817)
26. Saha C, Eckert GJ, Ambrosius WT, Chun TY, Wagner MA, Zhao Q, et al. Improvement in blood pressure with inhibition of the epithelial sodium channel in blacks with hypertension. Hypertension 2005; 46:481-487. (Pubitemid 41376826)
27. de Leeuw PW, Ruilope LM, Palmer CR, Brown MJ, Castaigne A, Mancia G, et al. Clinical significance of renal function in hypertensive patients at high risk: results from the INSIGHT trial. Arch Intern Med 2004; 164:2459-2464. (Pubitemid 39628073)
28. Lambers HJ, Holtkamp FA, Parving HH, Navis GJ, Lewis JB, Ritz E, et al. Moderation of dietary sodium potentiates the renal and cardiovascular protective effects of angiotensin receptor blockers. Kidney Int 2012; 82:330-337.
29. Lunetta M, Barbagallo A, Crimi S, Di MM, Sangiorgio L, Mughini L. Hypertension and related risk factors in type 2 diabetes mellitus. Minerva Endocrinol 1999; 24:45-50.
30. Dao HH, Essalihi R, Bouvet C, Moreau P. Evolution and modulation of age-related medial elastocalcinosis: impact on large artery stiffness and isolated systolic hypertension. Cardiovasc Res 2005; 66:307-317. (Pubitemid 40471045)
31. Sappino AP, Huarte J, Vassalli JD, Belin D. Sites of synthesis of urokinase and tissue-type plasminogen activators in the murine kidney. J Clin Invest 1991; 87:962-970.
32. Wagner SN, Atkinson MJ, Wagner C, Hofler H, Schmitt M, Wilhelm O. Sites of urokinase-type plasminogen activator expression and distribution of its receptor in the normal human kidney. Histochem Cell Biol 1996; 105:53-60. (Pubitemid 26041573)
33. Kenichi M, Masanobu M, Takehiko K, Shoko T, Akira F, Katsushige A, et al. Renal synthesis of urokinase type-plasminogen activator, its receptor, and plasminogen activator inhibitor-1 in diabetic nephropathy in rats: modulation by angiotensin-converting-enzyme inhibitor. J Lab Clin Med 2004; 144:69-77. (Pubitemid 39119805)
34. Bolon I, Zhou HM, Charron Y, Wohlwend A, Vassalli JD. Plasminogen mediates the pathological effects of urokinase-type plasminogen activator overexpression. Am J Pathol 2004; 164:2299-2304 (Pubitemid 38669375)